Armodafinil 50mg Tablet is a prescription wakefulness-promoting medicine containing 50mg of armodafinil, the R-enantiomer of modafinil. It is used in adults to improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work disorder (SWD).
Armodafinil is the generic medicine name, while Nuvigil® is the established brand name associated with armodafinil. The U.S. FDA-approved product labeling identifies armodafinil tablets in 50mg, 150mg, 200mg and 250mg strengths, and current U.S. DailyMed listings include authorized generic armodafinil 50mg tablets.
The regulatory status, manufacturer, brand availability, prescription requirements and permitted indications may differ between the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia. The actual product being supplied should therefore be described according to its manufacturer and authorization in the destination market.
Current U.S. DailyMed listings confirm 50mg armodafinil tablets and identify certain products as authorized generics under the original Nuvigil NDA.
Armodafinil is prescribed to improve wakefulness in adults with excessive sleepiness associated with:
For OSA, armodafinil is intended to address excessive sleepiness rather than the underlying airway obstruction. Patients with OSA should continue appropriate treatment for the underlying condition, such as CPAP when prescribed.
Narcolepsy is a neurological sleep disorder characterized by excessive daytime sleepiness and other disturbances of normal sleep-wake regulation.
Armodafinil promotes wakefulness and may help adults with narcolepsy remain more alert during the daytime. Treatment should be prescribed and monitored by a qualified healthcare professional.
Armodafinil may be prescribed for residual excessive daytime sleepiness associated with obstructive sleep apnea.
It does not mechanically open the airway or cure the underlying obstruction. The FDA labeling specifically states that armodafinil treats excessive sleepiness and is not treatment for the underlying obstruction. Appropriate primary OSA therapy should be addressed before or alongside treatment for persistent sleepiness.
Shift work disorder can occur when work schedules conflict with the body’s normal sleep-wake cycle.
Armodafinil is approved for improving wakefulness in adults with excessive sleepiness associated with shift work disorder. U.S. labeling recommends a 150mg dose approximately one hour before the work shift; therefore, 50mg should not be presented as the standard labeled SWD dose simply because the 50mg tablet strength exists.
Armodafinil is the R-enantiomer of modafinil. Its precise mechanism for promoting wakefulness has not been fully established.
It has pharmacological properties similar to those of modafinil, but armodafinil is a distinct active pharmaceutical ingredient. It is classified as a wakefulness-promoting agent rather than being described simply as a conventional amphetamine-type stimulant.
The commercially important distinction is:
Armodafinil 50mg = generic medicine / active pharmaceutical ingredient
Nuvigil® 50mg = branded armodafinil product
Nuvigil® is the reference brand associated with armodafinil. Generic armodafinil products are marketed by different manufacturers, and their excipients, packaging, appearance and regulatory status may differ.
A product should only be described as “Generic Nuvigil® 50mg” when that terminology accurately reflects its legal generic/equivalent status in the relevant market.
Armodafinil and modafinil are closely related wakefulness-promoting medicines but are not identical.
They should not be described as interchangeable products solely because they belong to the same therapeutic category. Treatment selection and dosing should be determined by the prescribing healthcare professional.
Armodafinil tablets are commercially available in several strengths.
Current U.S. labeling identifies:
The 50mg tablet is therefore a recognized dosage strength, although the labeled recommended dose for a particular indication may be higher. The presence of a 50mg tablet does not mean that 50mg is the standard dose for every condition.
Armodafinil dosage depends on the condition being treated and individual patient factors.
The current U.S. labeling recommends:
Severe hepatic impairment may require dosage reduction, and lower doses may be considered in geriatric patients.
Therefore, Armodafinil 50mg should be used only according to an individualized prescription, rather than assuming the tablet strength represents the appropriate daily dose.
Potential adverse effects associated with armodafinil include:
More serious reactions can occur, including serious skin reactions, hypersensitivity reactions, psychiatric symptoms and cardiovascular effects.
Current U.S. prescribing information warns about serious rash, DRESS/multi-organ hypersensitivity, angioedema/anaphylaxis, psychiatric symptoms and cardiovascular considerations.
Patients taking armodafinil should be aware of the possibility of serious dermatological reactions.
The prescribing information warns about potentially severe skin reactions, including Stevens-Johnson syndrome. Treatment should be discontinued and medical attention sought at the first sign of a serious rash unless another clear cause has been established by a healthcare professional.
Armodafinil may be associated with psychiatric symptoms in susceptible individuals.
Particular caution is recommended in patients with a history of:
New or worsening psychiatric symptoms should be discussed promptly with the prescribing healthcare professional.
Armodafinil can affect cardiovascular parameters in some patients.
Patients with known cardiovascular disease, hypertension or other relevant cardiovascular risk factors should inform their healthcare provider before treatment. The prescribing information recommends consideration of increased monitoring in patients with known cardiovascular disease.
In the United States, armodafinil is classified as a Schedule IV controlled substance (C-IV) because it can be abused or lead to dependence.
Patients should keep the medication secure and should not sell, share or give their prescription medicine to another person.
Controlled-drug classification and prescription regulations may differ between countries.
Armodafinil can affect the metabolism of other medicines and may interact with several classes of drugs.
Patients should tell their healthcare professional about all prescription medicines, non-prescription medicines, supplements and hormonal contraceptives they use.
Particular attention may be required for medicines metabolized through CYP pathways and for hormonal contraceptives because armodafinil can reduce the effectiveness of steroidal contraceptives. A healthcare professional should review the complete medication list before treatment.
Armodafinil 50mg Tablet has strong commercial search intent around the generic medicine, reference brand, strength, prescription status and international availability.
High-intent searches include:
Armodafinil 50mg Tablet, Armodafinil 50mg, Generic Nuvigil 50mg, Nuvigil 50mg Generic, Armodafinil 50mg Price, Buy Armodafinil 50mg, Armodafinil 50mg Online, Armodafinil 50mg Tablets, Generic Armodafinil 50mg, Armodafinil 50mg Pharmacy, Armodafinil 50mg Supplier, Armodafinil 50mg International Pharmacy and Armodafinil 50mg Worldwide Shipping.
Availability and legal supply requirements vary by destination. For international pharmaceutical ecommerce, the actual manufacturer, authorization, prescription status and import requirements should be verified for the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
Armodafinil 50mg Tablet is a prescription oral medicine containing 50mg of armodafinil, a wakefulness-promoting agent used in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work disorder.
Nuvigil® is the reference branded product containing armodafinil. Generic armodafinil 50mg contains the same active pharmaceutical ingredient, but the actual product’s regulatory equivalence, manufacturer and formulation should be verified in the relevant market.
Yes. Armodafinil is the generic name of the active medicine. Nuvigil® is a brand name associated with armodafinil.
No. Armodafinil is the R-enantiomer of modafinil, whereas modafinil contains both R- and S-enantiomers. They are related medicines but are not identical.
Armodafinil is indicated to improve wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work disorder.
Not generally for the labeled adult indications in the U.S. The recommended labeled doses are typically 150–250mg for narcolepsy and OSA and 150mg for shift work disorder. A 50mg tablet is an available strength and may be prescribed in particular circumstances at the clinician’s discretion.
Armodafinil is indicated for excessive sleepiness associated with OSA, but it does not treat the underlying airway obstruction. Appropriate treatment of OSA should continue as directed by the healthcare professional.
Armodafinil is generally classified as a wakefulness-promoting agent. It is pharmacologically related to modafinil and is not the same as traditional amphetamine-type stimulant medicines.
Insomnia can occur with armodafinil because it promotes wakefulness. The timing of administration is therefore important and should follow the prescribed regimen.
Armodafinil is a prescription medicine. In the United States it is also classified as a Schedule IV controlled substance. Prescription and controlled-drug requirements differ between countries.
Armodafinil is a prescription medicine. Online purchasing should be through an appropriately licensed pharmacy or authorized supplier and must comply with the prescription, controlled-drug and import regulations of the destination country.
Yes. Current U.S. DailyMed records list 50mg armodafinil tablets from generic manufacturers, including authorized generic products.
Nuvigil® is a brand name. Armodafinil is the generic medicine name.
Nuvigil® is a branded armodafinil product, while generic armodafinil 50mg is supplied by other authorized manufacturers. The active ingredient is armodafinil; inactive ingredients, appearance, packaging and manufacturer can differ.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Armodafinil is a prescription medicine and, in the United States, a Schedule IV controlled substance. The appropriate strength and dosage depend on the patient’s diagnosis, medical history, other medicines and response to treatment. Always use armodafinil only as prescribed by a qualified healthcare professional. Regulatory status, indications, prescription requirements, brand availability and import rules may vary by country.
Last Updated: September 6, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.